INTRODUCTION

43
Tuberculosis (TB) is the leading cause of mortality from an infectious agent 44 globally (1) and its treatment includes six-month long therapy with combinations of drugs.
45
Development of newer drugs with superior efficacy and safety is urgently required to shorten the 46 treatment duration as well as to manage drug-resistant TB effectively. Pathogen-targeted 47 treatment is the preferred choice, however, host-directed approaches are being increasingly between untreated and FX11-treated conditions (Fig. 1E ).
92
Although FX11 is an analog of anti-bacterial gossypol (17), we found that FX11 is (Fig. 1H) . We conclude that the bioenergetics effects of FX11 are highly host- Fig. 2A; Fig. S2A ) with less apparent effect on splenic CFU.
133
Administered dose of FX11 is similar to those in a previous study (14) , and further dose 134 increment is restricted due to poor compound solubility. Furthermore, complete inhibition of
135
LDHA could result in adverse events as it is essential for cellular homeostasis.
136
TB granulomas in C57BL/6J mice rarely progress into necrosis, whereas Nos2 (Fig. 2C; Fig. S3 ). Nonetheless, FX11 
402
Fluorescence images were recorded using a Leica SP8 confocal or a Leica DMR widefield 403 microscope (equipped with bandpass filter blocks and a Jenoptik ProgRes MF USB camera).
404
Complete tissue sections were digitized using a ZEISS Axioscan Z1 slide scanner. 1C and D) . 504 Parameter P values Non-Gly acidification 0.11 (NS) Glycolytic capacity 8.569e-09 (***) Glycolysis 0.85 (NS) Glycolytic reserve 6.883e-15 (***)
